FBRX - Forte Biosciences, Inc.

28.76
-1.520   -5.285%

Share volume: 246,458
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$30.28
-1.52
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 22%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.17%
1 Month
-3.52%
3 Months
45.69%
6 Months
158.40%
1 Year
342.46%
2 Year
3,637.98%
Key data
Stock price
$28.76
P/E Ratio 
0.00
DAY RANGE
$28.50 - $31.22
EPS 
-$4.41
52 WEEK RANGE
$4.90 - $35.62
52 WEEK CHANGE
$386.63
MARKET CAP 
186.493 M
YIELD 
N/A
SHARES OUTSTANDING 
35.588 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$247,313
AVERAGE 30 VOLUME 
$196,443
Company detail
CEO: Paul A. Wagner
Region: US
Website: fortebiorx.com
Employees: 5
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Recent news